Integra lifesciences (NASDAQ:IART) is scheduled to be announcing its earnings results before the market opens on Wednesday, April 25th. Analysts expect the company to announce earnings of $0.49 per share for the quarter. Integra lifesciences has set its FY18 guidance at $2.25-2.35 EPS.
Integra lifesciences (NASDAQ:IART) last released its earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. The company had revenue of $368.60 million during the quarter, compared to the consensus estimate of $362.64 million. Integra lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The firm’s quarterly revenue was up 44.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.52 earnings per share. On average, analysts expect Integra lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
IART stock opened at $56.20 on Monday. The firm has a market cap of $4,437.62, a PE ratio of 29.12, a PEG ratio of 1.73 and a beta of 0.65. Integra lifesciences has a twelve month low of $41.51 and a twelve month high of $58.17. The company has a quick ratio of 1.51, a current ratio of 2.36 and a debt-to-equity ratio of 1.85.
A number of equities research analysts have recently weighed in on IART shares. Zacks Investment Research upgraded Integra lifesciences from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. JPMorgan Chase lifted their price objective on Integra lifesciences from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 11th. Oppenheimer reaffirmed a “buy” rating on shares of Integra lifesciences in a research note on Thursday, March 22nd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $52.00 price objective on shares of Integra lifesciences in a research note on Friday, January 5th. Finally, BTIG Research initiated coverage on Integra lifesciences in a research note on Thursday, April 5th. They set a “neutral” rating and a $56.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Integra lifesciences currently has an average rating of “Hold” and an average price target of $55.82.
ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3381612/integra-lifesciences-iart-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Integra lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.